Jazz Pharmaceuticals (JAZZ) is unlikely to see a meaningful Q2-driven stock reaction, with investors focused instead on the expected approval and launch of Ziihera in gastroesophageal adenocarcinoma, or GEA, as the key near-term catalyst, UBS said in a note Wednesday.

The analysts said that while the stock has lagged the recent biotech rally, this is largely because gains have been concentrated in smaller-cap companies driven by mergers and acquisitions activity, and some investors had already expected National Comprehensive Cancer Network guideline inclusion for GEA, which has yet to occur.

"We note that Jazz stock outperformed in Q4 2025/Q1 2026, but we believe the Q2 update could have a marginal impact on the stock," they added.

The company has more meaningful near-term upside from the expected approval and launch of Ziihera in GEA, with a PDUFA date of Aug. 25, according to the note.

Longer term, additional value creation is expected from business development and pipeline expansion, as well as breast cancer topline data expected in late 2027 to early 2028. "Despite some erosion to the sleep franchise (generics), we believe the base business should remain stable as we approach GEA's launch," the analysts said.

The analysts expect Q2 total revenue of $1.1 billion, broadly in line with consensus, and full-year 2026 revenue of $4.4 billion versus consensus of $4.5 billion. Q2 earnings per share are expected to be $6.29 versus the consensus of $6.19 and the prior estimate of $6.49.

UBS has a buy rating and a $307 price target on Jazz Pharmaceuticals.

Price: 241.42, Change: +3.91, Percent Change: +1.65